Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Metadata
Title
Serum Lipids and Outcome of Early-stage Breast Cancer: Results of a Prospective Cohort Study
Authors
Mala Bahl
Marguerite Ennis
Ian F. Tannock
Jan E. Hux
Kathleen I. Pritchard
Jarley Koo
Pamela J. Goodwin
Publication date
01-11-2005
Publisher
Kluwer Academic Publishers
Published in
Breast Cancer Research and Treatment / Issue 2/2005
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-005-6654-9

Other articles of this Issue 2/2005

Breast Cancer Research and Treatment 2/2005 Go to the issue

Report

Tissue Inhibitor of Metalloproteinases-1 Stimulates Gene Expression in MDA-MB-435 Human Breast Cancer Cells by Means of its Ability to Inhibit Metalloproteinases

Report

Polymorphisms of the BRCA2 and RAD51 Genes in Breast Cancer

Report

Estrogen Receptor Beta (ESR2) Polymorphisms in Familial and Sporadic Breast Cancer

Report

Is Adjuvant Therapy for Older Patients with Node (+) Early Breast Cancercost-effective?*

Report

High Incidence of 4153delA BRCA1 Gene Mutations in Lithuanian Breast- and Breast-ovarian Cancer Families

Report

Progesterone Pre-treatment Potentiates EGF Pathway Signaling in The Breast Cancer Cell Line ZR-75*
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits